Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine

Post-COVID-19 Condition (PCC), as defined by the World Health Organization (WHO), currently lacks any regulatory-approved treatments and is characterized by persistent and debilitating cognitive impairment and...

Source: Annals of General Psychiatry - February 29, 2024 Category: Psychiatry Authors: Angela T.H. Kwan, Gia Han Le, Ziji Guo, Felicia Ceban, Kayla M. Teopiz, Taeho Greg Rhee, Roger Ho, Joshua D. Di Vincenzo, Sebastian Badulescu, Shakila Meshkat, Bing Cao, Joshua D. Rosenblat, Donovan A. Dev, Lee Phan, Mehala Subramaniapillai and Roger S. M Tags: Research Source Type: research